Breckenridge Company Profile

What is the competitive landscape for BRECKENRIDGE

BRECKENRIDGE has forty-three approved drugs.

There are two tentative approvals on BRECKENRIDGE drugs.

Summary for Breckenridge

US Patents:	0
Tradenames:	42
Ingredients:	42
NDAs:	43
Patent Litigation for Breckenridge:	See patent lawsuits for Breckenridge
PTAB Cases with Breckenridge as petitioner:	See PTAB cases with Breckenridge as petitioner

Drugs and US Patents for Breckenridge

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Breckenridge	EVEROLIMUS	everolimus	TABLET;ORAL	205432-001	May 20, 2021	AB	RX	No	No
Breckenridge	POMALIDOMIDE	pomalidomide	CAPSULE;ORAL	210111-004	Oct 30, 2020	AB	RX	No	No
Breckenridge	EPLERENONE	eplerenone	TABLET;ORAL	208283-001	Sep 14, 2018	AB	RX	No	No
Breckenridge	TRIMIPRAMINE MALEATE	trimipramine maleate	CAPSULE;ORAL	208127-003	Apr 15, 2016	AB	RX	No	No
Breckenridge	PENICILLAMINE	penicillamine	CAPSULE;ORAL	215409-001	Aug 23, 2021	AB	RX	No	No
Breckenridge	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205447-002	Feb 14, 2023		DISCN	No	No
Breckenridge	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	209818-001	May 20, 2019		DISCN	No	No

Paragraph IV (Patent) Challenges for BRECKENRIDGE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-release Tablets	20 mg		2015-06-03

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Breckenridge
• Breckenridge Pharm

Pharmaceutical Competitive Landscape Analysis: Breckenridge – Market Position, Strengths & Strategic Insights

Last updated: January 7, 2026

Summary

Breckenridge Pharmaceutical (Breckenridge) positions itself as a specialized generics and branded pharmaceuticals company, primarily serving the United States market. This analysis evaluates Breckenridge’s current market standing, core strengths, competitive advantages, and strategic initiatives within the ever-evolving pharmaceutical landscape. The report synthesizes data from industry reports, regulatory filings, and company disclosures to provide a comprehensive view of Breckenridge’s market position, while comparing it with key competitors such as Teva, Mylan (now part of Viatris), Sandoz, and others.

Market Context & Overview

Pharmaceutical Industry Dynamics (2023-2025)

Aspect	Details
Global Market Size	USD 1.42 trillion (2022), projected CAGR of 3.3% through 2027 [1]
US Market Share	Approx. 42% of global pharmaceutical sales in 2022 [2]
Generics Market Growth	CAGR of 7.1% (2023-2028), driven by patent expirations and price competition [3]
Biosimilars & Specialty Drugs	Increasing focus, yet generics remain key for price reductions [4]

Breckenridge’s Place in Market

Breckenridge operates predominantly in the generics sector, with a strategic expansion into niche branded drugs. It maintains a targeted portfolio of over 300 products, with a focus on sterile injectables, controlled substances, and niche therapeutics.

Market Position & Competitive Standing

Market Share & Revenue Landscape

Company	2022 Revenue (USD millions)	Estimated US Generics Market Share	Notable Products
Breckenridge	~$400	~0.3%	Injectable steroids, controlled substances
Teva	~$5,255	~2.4%	Multiple generics, biosimilars
Mylan / Viatris	~$4,877	~1.9%	Vaccines, injectables
Sandoz (Novartis)	~$9,000	~4.0%	Biosimilars, generics

Note: Exact market share data is proprietary; estimates are derived from revenue proportions and industry reports.

Competitive Strengths

Strength	Details	Implication for Market Position
Niche Focus	Specializes in sterile injectables and controlled substances	Differentiates from leading mass-market generics
Regulatory Compliance	Consistent FDA inspections; robust compliance systems	Maintains uninterrupted product supply
Product Portfolio	Over 300 SKUs, including complex generics	Diversifies revenue streams and reduces heavy reliance on any single product
Manufacturing Capabilities	State-of-the-art sterile facilities	Enables high-quality and compliant production

Weaknesses & Challenges

Weakness/Challenge	Details	Strategic Implication
Limited Scale Compared to Industry Giants	Smaller R&D and marketing budget	Competition on pricing and distribution channels
Market Penetration	Limited geographic presence outside the US	Opportunities for expansion in developed and emerging markets
R&D Investment	Lower than competitors with extensive innovation pipelines	Potential risk of product obsolescence

Strategic Insights & Competitive Analysis

Key Differentiators

Feature	Breckenridge Advantage	Industry Context
Focus on Complex Generics	Strengths in sterile injectables	Growing demand for complex generics due to patent cliff on branded drugs
Controlled Substance Portfolio	Strong regulatory oversight	Critical amid opioid crisis management and regulatory scrutiny
Agility & Niche Targeting	Rapid response to market shifts	Smaller size enhances operational flexibility

Strategic Initiatives & Growth Opportunities

Initiative	Objective	Potential Impact
Portfolio Expansion	Add complex generics and biosimilars	Capture more market share and healthcare savings mandates
Geographic Diversification	Enter Canadian and European markets	Access new revenue streams and reduce reliance on US market
M&A Activity	Acquire niche biotech firms or smaller generics companies	Accelerate growth and diversify product pipeline
R&D Enhancement	Invest in innovative formulations	Differentiate from competitors and justify premium pricing

Competitive Comparison Table (2023)

Company	Market Share	Focus Areas	R&D Spend (USD millions)	Notable Strategic Moves
Breckenridge	~0.3%	Sterile Injectables, Controlled Substances	<$50	Focused niche growth, US-centric
Teva	~2.4%	Broad Mass-Generics, Biosimilars	~$300	Portfolio divestitures, biosimilar focus
Mylan / Viatris	~1.9%	Vaccines, Complex Generics	~$250	Portfolio consolidation, global expansion
Sandoz	~4.0%	Biosimilars, Complex Generics	~$400	Biosimilar pipeline expansion

Regulatory & Policy Environment Impact

US FDA Regulatory Landscape

• Increasing emphasis on quality and inspection standards, especially for sterile products.
• Initiatives to streamline ANDA approvals for complex generics [5].
• Crackdowns on controlled substance manufacturing practices due to opioid epidemic oversight.

Pricing & Reimbursement Trends

• Continued downward pressure on generic drug prices.
• Policy shifts favoring biosimilars and value-based pricing models.
• Opportunities derived from government programs like Medicaid and Medicare.

Deep-Dive Comparison: Breckenridge vs. Key Competitors

Aspect	Breckenridge	Teva	Viatris	Sandoz
Core Focus	Niche sterile generics	Broad generics + biosimilars	Diversified generics & biosimilars	Biosimilars & complex generics
Revenue (2022)	~$400M	~$5.3B	~$4.9B	~$9B
US Market Share	Approx. 0.3%	2.4%	1.9%	4.0%
Strategic Strengths	Agility, niche focus	Scale, R&D	Diversification, global reach	Innovation in biosimilars
Challenges	Limited scale, market reach	Patent cliffs, cost pressure	Integration, R&D costs	Market penetration, pricing pressures

Conclusions & Strategic Recommendations

• Leverage niche expertise: Breckenridge’s focused portfolio of sterile injectables and controlled substances enables it to compete effectively in a specialized segment. Augmenting this with targeted biosimilar development could further differentiate the company.

• Expand geographic reach: While US market dominance remains, expanding into Canada, Europe, and emerging markets can buffer against US market pressures and diversify revenue.

• Invest in R&D: Developing complex generics and biosimilars will enable Breckenridge to command higher margins and sustain growth amid aggressive price competition.

• Pursue strategic acquisitions: Acquiring smaller firms specializing in niche formulations or technologies can accelerate innovation and expand product portfolios.

• Enhance regulatory compliance & quality: Maintaining rigorous standards is critical for uninterrupted market access, especially with heightened FDA scrutiny.

Key Takeaways

• Breckenridge holds a unique, highly specialized niche in sterile injectables and controlled substances, offering resilience amid generic market commoditization.
• The company’s strengths in regulatory compliance, product diversification, and manufacturing agility position it well for targeted growth.
• Challenges include limited scale compared to industry giants, necessitating strategic expansion and investment.
• Opportunities exist in biosimilars, complex generics, and geographic diversification, supported by regulatory shifts favoring innovation.
• Strategic focus on R&D, M&A, and market expansion will be vital to sustain competitive advantage and achieve growth objectives.

---

FAQs

1. What are Breckenridge’s main competitive advantages?
   Its focus on niche sterile injectables, robust regulatory compliance, and manufacturing agility differentiate it within the generics space.

2. How does Breckenridge’s market share compare to industry leaders?
   With an estimated US market share of approximately 0.3%, Breckenridge’s scale is significantly smaller than Teva or Sandoz, but its specialized portfolio allows targeted positioning.

3. What growth strategies should Breckenridge pursue?
   Expanding into biosimilars, broadening geographic presence, investing in R&D for complex generics, and acquiring niche firms are key strategies.

4. What regulatory challenges does Breckenridge face?
   Maintaining high-quality manufacturing standards amid increasing FDA scrutiny, especially for sterile and controlled substances, is critical.

5. Where are the growth opportunities outside the US?
   Canada, Europe, and emerging markets offer expanding demand for generics, especially complex formulations and biosimilars, presenting avenues for diversification.

---

References

[1] IQVIA, Global Medicines Data 2022.
[2] Statista, Global Pharmaceutical Market Share by Region, 2022.
[3] Evaluate Pharma, Generics Market Forecast, 2023-2028.
[4] FDA, Biosimilars Policy & Guidance, 2022.
[5] FDA, Generic Drug Approval Process, 2023.